Retinoids as a potential treatment for experimental puromycin-induced nephrosis

Area of Science:

• Nephrology
• Molecular Biology
• Immunology

Background:

• Puromycin aminonucleoside (PAN)-induced nephrosis models human minimal change disease.
• PAN causes proteinuria, podocyte damage, inflammation, and apoptosis in rats.
• Retinoic acid (RA) influences inflammation and apoptosis, relevant to PAN nephrosis pathology.

Purpose of the Study:

• To investigate the therapeutic effect of all-trans retinoic acid (tRA) in a rat model of PAN-induced nephrosis.
• To evaluate tRA's impact on podocyte injury, proteinuria, and renal inflammation.
• To assess tRA's role in inhibiting apoptosis in cultured podocytes.

Main Methods:

• Administered tRA before and after PAN injection in rats.
• Assessed proteinuria, podocyte morphology, and interstitial mononuclear cell infiltration.
• Measured renal expression of fibronectin and monocyte chemoattractant protein-1.
• Utilized TUNEL assays to evaluate apoptosis in cultured podocytes.

Main Results:

• tRA treatment significantly reversed proteinuria when given after PAN.
• Early tRA administration (pre- and post-PAN) protected podocytes, reducing edema and foot process effacement.
• tRA decreased interstitial mononuclear cell infiltration and expression of fibronectin and MCP-1.
• tRA inhibited PAN-induced apoptosis in cultured podocytes.

Conclusions:

• tRA treatment protects podocytes and reduces inflammation in PAN nephrosis.
• tRA administration can prevent or reverse proteinuria in this model.
• Retinoids represent a potential therapeutic avenue for proteinuric kidney diseases involving mononuclear cell infiltration.